Dianthus Therapeutics Inc.宣布,其药物候选产品Claseprubart(Dnth103)在针对全身性重症肌无力的Magic 2期临床试验中取得积极结果,这些数据进一步支持了该药物的潜在同类最佳特性。
Dianthus Therapeutics Inc.宣布,其药物候选产品Claseprubart(Dnth103)在针对全身性重症肌无力的Magic 2期临床试验中取得积极结果,这些数据进一步支持了该药物的潜在同类最佳特性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.